3io Therapeutics is a Toronto-based company focused on the development of next generation anti-cancer immunotherapies for patients with high, unmet clinical needs. The company’s core technology is an oncolytic virus therapy with a unique mode of action that activates the immune system to attack tumours. The virus is non-pathogenic in humans, and has the potential for systemic delivery and the targeting of tumor metastases. The company is currently working on the development of therapies for the treatment of KRAS-mutated lung, colorectal and pancreatic cancer.

In partnership with McMaster University, 3io Therapeutics is developing a novel oncolytic viral therapy for KRAS-mutated lung, pancreatic and colorectal cancers.